Though used frequently to treat farm animals and on occasion household pets, flumequine was also used to treat urinary tract infections in humans.  Flumequine, was used transiently treat urinary infections<ref name=pmid3356617/> until ocular toxicity was reported.<ref name=pmid6378414>{{cite journal |vauthors=Sirbat D, Saudax E, Hurault de Ligny B, Hachet E, Abellan P, George JL |title=[Serous macular detachment and treatment with flumequine (Apurone &#61; urinary antibacterial). Apropos of 2 cases] |language=French |journal=Bulletin Des Sociétés D'ophtalmologie De France |volume=83 |issue=8–9 |pages=1019–21 |year=1983 |pmid=6378414}}</ref><ref name=pmid6506018>{{cite journal |vauthors=Hurault de Ligny B, Sirbat D, Kessler M, Trechot P, Chanliau J |title=[Ocular side effects of flumequine. 3 cases of macular involvement] |language=French |journal=Thérapie |volume=39 |issue=5 |pages=595–600 |year=1984 |pmid=6506018}}</ref><ref name=pmid10997595>{{cite journal |author=Ball P |title=Quinolone generations: natural history or natural selection? |journal=The Journal of Antimicrobial Chemotherapy |volume=46 |issue=Suppl T1 |pages=17–24 |date=July 2000 |pmid=10997595 |url=http://jac.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=10997595 |doi=10.1093/oxfordjournals.jac.a020889}}</ref> as well as liver damage<ref>{{cite journal |vauthors=Dubois A, Janbon C, Pignodel C, Marty-Double C |title=[Immunoallergic hepatitis induced by flumequine] |language=French |journal=Gastroentérologie Clinique et Biologique |volume=7 |issue=2 |pages=217–8 |date=February 1983 |pmid=6840466}}</ref> and anaphylactic shock.<ref name=pmid1299991>{{cite journal |vauthors=Pinzani V, Gennaro G, Petit P, Blayac JP |title=[Anaphylactic shock induced by flumequine] |language=French |journal=Thérapie |volume=47 |issue=5 |page=440 |year=1992 |pmid=1299991}}</ref><ref name="Sebbah JL. Presse Med p 28">{{cite journal |vauthors=Marsepoil T, Blin F, Lo JM, Horel D'Ancona F, Sebbah JL |title=[A case of anaphylactic shock induced by flumequine] |language=French |journal=Presse Médicale |volume=14 |issue=32 |page=1712 |date=September 1985 |pmid=2932732}}</ref>

 
This mechanism can also affect mammalian cell replication. In particular, some congeners of this drug family (for example those that contain the C-8 fluorine),<ref>{{cite journal |vauthors=Robinson MJ, Martin BA, Gootz TD, McGuirk PR, Osheroff N |title=Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group |journal=[[Antimicrobial Agents and Chemotherapy]] |volume=36 |issue=4 |pages=751–6 |date=April 1992 |pmid=1323952 |pmc=189387 |url=http://aac.asm.org/cgi/pmidlookup?view=long&pmid=1323952 |doi=10.1128/aac.36.4.751}}</ref> display high activity not only against bacterial topoisomerases, but also against eukaryotic topoisomerases and are toxic to cultured mammalian cells and ''in vivo'' tumor models.<ref name="pmid14529452">{{cite journal |vauthors=Sissi C, Palumbo M |title=The quinolone family: from antibacterial to anticancer agents |journal=Current Medicinal Chemistry |volume=3 |issue=6 |pages=439–50 |date=November 2003 |pmid=14529452 |doi=10.2174/1568011033482279 |quote=The present review focuses on the structural modifications responsible for the transformation of an antibacterial into an anticancer agent. Indeed, a distinctive feature of drugs based on the quinolone structure is their remarkable ability to target different type II topoisomerase enzymes. In particular, some congeners of this drug family display high activity not only against bacterial topoisomerases but also against eukaryotic topoisomerases and are toxic to cultured mammalian cells and in vivo tumor models}}</ref>

 
Recent studies have demonstrated a correlation between mammalian cell cytotoxicity of the quinolones and the induction of micronuclei.<ref>{{cite journal |vauthors=Hosomi J, Maeda A, Oomori Y, Irikura T, Yokota T |year=1988 |title=Mutagenicity of Norfloxacin and AM-833 in Bacteria and Mammalian Cells |journal=Reviews of Infectious Diseases |volume=10 |issue=Supplement 1 |pages=S148–9 |jstor=4454399}}</ref><ref>{{cite journal |vauthors=Forsgren A, Bredberg A, Pardee AB, Schlossman SF, Tedder TF |title=Effects of ciprofloxacin on eucaryotic pyrimidine nucleotide biosynthesis and cell growth |journal=Antimicrobial Agents and Chemotherapy |volume=31 |issue=5 |pages=774–9 |date=May 1987 |pmid=3606077 |pmc=174831 |url=http://aac.asm.org/cgi/pmidlookup?view=long&pmid=3606077 |doi=10.1128/AAC.31.5.774}}</ref><ref>{{cite journal |vauthors=Gootz TD, Barrett JF, Sutcliffe JA |title=Inhibitory effects of quinolone antibacterial agents on eucaryotic topoisomerases and related test systems |journal=Antimicrobial Agents and Chemotherapy |volume=34 |issue=1 |pages=8–12 |date=January 1990 |pmid=2158274 |pmc=171510 |url=http://aac.asm.org/cgi/pmidlookup?view=long&pmid=2158274 |doi=10.1128/AAC.34.1.8}}</ref><ref>{{cite journal |vauthors=Lawrence JW, Darkin-Rattray S, Xie F, Neims AH, Rowe TC |title=4-Quinolones cause a selective loss of mitochondrial DNA from mouse L1210 leukemia cells |journal=Journal of Cellular Biochemistry |volume=51 |issue=2 |pages=165–74 |date=February 1993 |pmid=8440750 |doi=10.1002/jcb.240510208}}</ref>

 
* [[Adverse effects of fluoroquinolones]]
